Pangaea Oncology among the finalists competing for Best Listed European company in expansion

Barcelona, September 6th 2017.- Pangaea Oncology has been shortlisted for the Rising Star prize for best company in expansion listed on the European alternative stock markets. The finalists were announced yesterday by the Federation of European Securities Exchanges (FESE).

      Pangaea, a healthcare company specializing in precision oncology, was listed on Madrid’s Alternative Stock Market (MAB) on December 29th 2016 and counts leading global pharmaceutical and biotech companies among its clients.

The company is one of just three finalists selected from 29 listed EU companies from 11 countries, with market capitalization of up to €50 million. The award for this category, promoted by the European Commission as part of the 5th European Small and Mid-Cap Awards, is intended to foster and reward the success of listed SMEs in the process of expansion within the EU.  

An independent panel will decide the winners in a ceremony organized by FESE and European Issuers on the 22nd of November in Brussels.  

We use first and third party cookies to track your browsing habits on our website in order to provide you with better quality and security, and improve the services offered through this website. If users do not explicitly confirm that they consent to the installation of cookies but continue to browse our website, we will assume that they have agreed and we will inform them accordingly about the possibility of blocking or deleting any previously installed cookies by adjusting their browser settings. You can find out more about cookies in our "Cookie Policy".